ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Amarin Corporation Plc Sponsored ADR (AMRN) Report Updated: Sep 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Amarin Corporation Plc Sponsored ADR (AMRN)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: CBPO, ENTA, RGEN, MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Amarin Corporation Plc Sponsored ADR© quotemedia

Company Profile

Amarin Corporation plc, a late-stage biopharmaceutical company, focuses on developing the treatment for cardiovascular disease in the field of lipid science. Its lead product candidate includes AMR101, a prescription-only omega-3 fatty acid comprising icosapent ethyl, or ethyl-EPA for the treatment of patients with very high triglyceride levels and high triglyceride levels or hypertriglyceridemia. The company, formerly known as Ethical Holdings plc, was founded in 1989 and is headquartered in Dublin, Ireland.

Recent News: Amarin Corporation Plc Sponsored ADR